Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT06124157)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL): a one-minute explainerNCT061241571 min

Biospecimen Collection trial for B Acute Lymphoblastic Leukemia (NCT06124157). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for newly diagnosed, CD19-positive Philadelphia-positive or ABL-class Philadelphia-like B-cell acute lymphoblastic leukemia. Enrollment age must exceed 365 days: COG patients must be under 22, AIEOP-BFM under 18, and ALLTogether under 46.

The idea: combine chemotherapy and blinatumomab, which links immune cells to leukemia, with growth-signal blockers. PDGFRB-fusion cases receive imatinib; the other eligible groups receive dasatinib. Initial chemotherapy timing and genetic testing determine entry. Researchers measure outcomes and safety.

This phase 2 study plans 222 patients. NCI sponsors it; 145 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.